Abstract
Naming impairment in Alzheimer’s disease dementia (AD) is associated with atrophy of the left anterior temporal lobe (ATL). We aimed to elucidate if regional cerebral glucose metabolism, as a biomarker of synaptic dysfunction and neurodegeneration, of the left ATL predicts naming impairment, and if amyloid-beta (Aβ) deposition, a pathological hallmark of AD, contributes to the prediction.
Twenty-nine patients with AD underwent combined [11C]PIB and [18F]FDG PET examinations for assessment of Aβ load and regional cerebral glucose metabolism. An a priori defined region of interest was used for regional PET analyses of the left ATL. In linear stepwise regression analyses, glucose metabolism of the left ATL was the only significant predictor of naming performance, independent of sex, age, and education. Neither regional nor global Aβ load contributed to the prediction.
Left ATL glucose metabolism predicts naming impairment in AD. By contrast, Aβ deposition does not predict naming impairment.
Keywords: Alzheimer’s disease, amyloid, confrontation naming, Pittsburgh compound B, positron emission tomography.
Current Alzheimer Research
Title:Left Anterior Temporal Glucose Metabolism and not Amyloid-beta Load Predicts Naming Impairment in Alzheimer’s Disease
Volume: 13 Issue: 6
Author(s): Lars Frings, Timo S. Spehl, Michael Hüll and Philipp T. Meyer
Affiliation:
Keywords: Alzheimer’s disease, amyloid, confrontation naming, Pittsburgh compound B, positron emission tomography.
Abstract: Naming impairment in Alzheimer’s disease dementia (AD) is associated with atrophy of the left anterior temporal lobe (ATL). We aimed to elucidate if regional cerebral glucose metabolism, as a biomarker of synaptic dysfunction and neurodegeneration, of the left ATL predicts naming impairment, and if amyloid-beta (Aβ) deposition, a pathological hallmark of AD, contributes to the prediction.
Twenty-nine patients with AD underwent combined [11C]PIB and [18F]FDG PET examinations for assessment of Aβ load and regional cerebral glucose metabolism. An a priori defined region of interest was used for regional PET analyses of the left ATL. In linear stepwise regression analyses, glucose metabolism of the left ATL was the only significant predictor of naming performance, independent of sex, age, and education. Neither regional nor global Aβ load contributed to the prediction.
Left ATL glucose metabolism predicts naming impairment in AD. By contrast, Aβ deposition does not predict naming impairment.
Export Options
About this article
Cite this article as:
Frings Lars, Spehl S. Timo, Hüll Michael and Meyer T. Philipp, Left Anterior Temporal Glucose Metabolism and not Amyloid-beta Load Predicts Naming Impairment in Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (6) . https://dx.doi.org/10.2174/1567205013666160322141955
DOI https://dx.doi.org/10.2174/1567205013666160322141955 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Amylin and its Receptors in Neurodegeneration
Current Protein & Peptide Science Asthma-COPD Overlap: A more Simplistic Approach
Current Respiratory Medicine Reviews Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer’s Disease
Current Alzheimer Research Editorial [Hot Topic:Advances in Alzheimer Therapy: Understanding Pharmacological Approaches to the Disease (Guest Editors: Ana Martinez, Debomoy K. Lahiri, Ezio Giacobini and Nigel H. Greig)]
Current Alzheimer Research Mechanisms of HIV Transcriptional Regulation by Drugs of Abuse
Current HIV Research Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology New Perspectives for the Diagnosis of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Multitarget Drugs of Plants Origin Acting on Alzheimer's Disease
Current Medicinal Chemistry Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column
Current Pharmaceutical Design Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Neurolological Disorders and Neuroprotection After Heart Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Recent Developments in Computer Aided Diagnosis for Lung Nodule Detection from CT images: A Review
Current Medical Imaging Locus (Coeruleus) Minoris Resistentiae in Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Current Pharmaceutical Design